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Prostate cancer is the second most frequently diagnosed cancer in men in the United States. Many
men with clinically localized prostate cancer survive for 15 years or more. Although early detection
and successful definitive treatments are increasingly common, a debate regarding how aggressively
to treat prostate cancer is ongoing because of the effect of aggressive treatment on the quality of life,
including sexual functioning. We examined current research on the effect of post-prostatectomy
radiation treatment on sexual functioning, and suggest a way in which patient desired outcomes
might be taken into consideration while making decisions with regard to the timing of radiation
therapy after prostatectomy.
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Introduction
Prostate cancer is the second most frequently
diagnosed cancer in men in the United States.
1
Many men with clinically localized prostate cancer
survive for 15 years or more. Although early
detection and successful definitive treatments are
becoming increasingly common, a debate regarding
how aggressively to treat prostate cancer is ongoing.
When surgical treatment is unable to remove all
evidence of tumor (margins are not clear, there is an
extraprostatic extension, seminal vesicles are in-
volved), radiation therapy may be considered to
decrease the risk of recurrence. Both initial radical
prostatectomy and radiation therapy have signifi-
cant effects on sexual functioning, thus decreasing
patients’ quality of life (QOL). We examined current
research on the effect of post-prostatectomy radia-
tion treatment on sexual functioning, and suggest a
way in which patient desired outcomes might be
taken into consideration while making decisions
with regard to the timing of radiation therapy after
prostatectomy.
Materials and methods
PubMed was searched for studies on radiation
therapy after prostatectomy, using the following
keywords: prostate cancer, adjuvant radiation
therapy after prostatectomy, salvage radiation
therapy after prostatectomy, QOL with post-prosta-
tectomy radiation therapy and sexual functioning
with post-prostatectomy radiation therapy. The
search included linked studies and yielded 20
articles and two comments. The goal of this review
is to summarize what is currently known about the
sexual sequelae of post-prostatectomy radiation
treatment to guide discussions with patients who
may be candidates for this intervention.
Institutional review board approval was not
required. The authors attest that they have no
financial and personal relationships among
themselves and with others that might bias their
work.
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The timing of post-prostatectomy radiation
treatment
Current research on post-prostatectomy radiation
therapy explicitly evaluates its effect on survival.
However, treatment need and effectiveness must
be weighed against the possibility of overtreatment
and long-term effects on the QOL.
2,3 Adjuvant
radiation therapy is typically delivered to men
with a high risk for recurrence, roughly 12–16 weeks
after prostatectomy, even without any evidence of
relapse. It is, by definition, more aggressive, because
it delivers radiation to a proportion of men who
would never have required radiation therapy. It
emphasizes disease control by being delivered when
tumor volume is at its lowest, but may affect erectile
functioning. The timing of adjuvant radiation
therapy often reflects the desire to protect urinary
functioning, which can resolve within months of
prostatectomy. Erectile recovery after nerve-sparing
surgery takes 18 months to 2 years,
4 which puts
erectile functioning at greater risk of permanent
damage. Adjuvant therapy (chemotherapy and/or
radiation) is commonly successful in the treatment
of breast, lung, colorectal and other malignancies.
Given the fact that, in prostate cancer, serum
biomarker—prostate-specific antigen (PSA)—can
herald clinical relapse B5 years in advance, the
merit of adjuvant therapy continues to be studied.
Salvage radiation therapy is delivered when patients
have evidence of a biochemical relapse with PSA or
a clinical relapse with evidence of local recurrence.
It can be seen as reactive to a relapse, at least
initially. It has the advantage of allowing the patient
to heal sexually after surgery and of avoiding
unnecessary additional treatment. However, the
protective value of salvage radiation therapy must
be balanced against a potential decline in the chance
of prostate cancer cure if radiation is deferred until
a time when its efficacy decreases. Factors that
might predict the success of salvage radiation are
the following: (1) a Gleason’s score of o8; (2)
a preradiation therapy PSA of o2.0ngml
 1; (3)
positive surgical margins; (4) pretreatment PSA
doubling time of 410 months; and (5) a lack of
invasion of seminal vesicles.
5 Patients with favor-
able characteristics for all five features had a 470%
chance of biochemical control 4 years after salvage
radiation therapy.
6
The effectiveness of adjuvant radiation therapy in
preventing PSA relapse and metastasis has been
described in several retrospective
7,8,9 and prospec-
tive
10,11 studies, with some studies also attempting
to determine factors that would predispose patients
to a positive response to adjuvant therapy.
12–14 The
long-term follow-up of the Southwest Oncology
Group adjuvant radiation therapy trial (SWOG
8794/RTOG 9019) with 12-year data
15 provides the
strongest support for the effectiveness of adjuvant
radiation therapy. The study cohort included 425
eligible men with pathological pT3N0M0 prostate
cancer who had undergone radical prostatectomy
and were found to have high-risk features: A total
of 211 were randomized into an observation
group, whereas 214 underwent adjuvant radiation
therapy within 10 working days of randomization.
At a median follow-up of over 12 years, 54% of
the observation group participants died or had
metastatic disease, but only 43% of the adjuvant
radiation therapy participants reached the same end
point. Median metastasis free survival was 12.9 and
14.7 years for the observation and treatment groups,
respectively. Similarly, a study reviewing biochem-
ical progression-free survival in the European
Organization for the Research and Treatment of
Cancer (EORTC/22911) found in a 5-year follow-up
of 1005 patients with clinical pT3N0M0, randomly
assigned to immediate postoperative radiation
therapy (N¼502) and observation (N¼503), that
adjuvant radiation therapy led to a significantly
improved likelihood of a biochemical relapse-free
survival.
16 Given the modest duration of this study’s
follow-up, the long-term risk of metastatic disease is
not yet known.
The debate with regard to adjuvant vs salvage
radiation continues on the basis of criticisms of the
SWOG study design, as well as on the utility of
comparing a cohort that was treated 20 years ago to
present day patients.
17,18 Although both the SWOG
and EORTC studies showed an improvement in
study end points, there are methodological issues
that compromise an unqualified acceptance of
these results, such as enrollment of patients in
both arms with detectable PSA after prostatectomy
(that is,. already in relapse), plus applying ‘early’
salvage radiation therapy to only B20% of relapsing
patients.
A recently published well-controlled German
study (Arbeitsgemeinschaft Radiologische Onko-
logie und Urologische Onkologie (ARO96-02/AUO
AP09/95)
19), which compared adjuvant radiation
therapy with observation, supports the conclusions
drawn by the SWOG 8794/RTOG 9019 and EORTC/
22911 studies. The researchers found a 20% reduc-
tion of risk of biochemical progression and local
relapse in the adjuvant arm.
A new study in the United Kingdom and Canada
(Radiotherapy and Androgen Deprivation In Combi-
nation After Local Surgery (RADICALS)
17) is at-
tempting to define more clearly postoperative
freedom from disease (undetectable PSA) and
criteria for timing salvage treatment. Patients with
high-risk pathological features are randomized to
receive adjuvant radiation therapy within 2 months.
The observation arm will proceed to salvage radia-
tion therapy as soon as patients’ PSA rises above
0.1ngml
 1. Men may be randomized additionally to
an adjuvant 6-month androgen-deprivation therapy.
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important to allow patients to know about them
while making treatment decisions. The benefit of
adjuvant therapy is becoming clear but it is not yet a
standard of care: overtreatment is a concern and
salvage therapy has been insufficiently well stu-
died.
20 A full review of the effect of the timing of
post-prostatectomy radiation therapy on survival is
beyond the scope of this paper. We have tried to
touch on this discussion to provide a context for
the consideration of decisions regarding sexual
recovery.
The effect of post-operative radiation therapy on
sexual functioning
Although the precise estimations of erectile dys-
function (ED) secondary to prostate cancer surgery
vary from study to study, more than 50% of men
suffer from it and find it upsetting. Studies by
Penson,
21 Schover,
22 Miller
4 and Sanda
23 and
collaborators have described both the magnitude of
the problem and patients’ reactions to this sexual
dysfunction.
Radiation therapy also has an effect on ED. The
decline is gradual, reaches a nadir at B18–24
months
24,25 and is stable thereafter. It has been
proposed that radiation may have an impact on
vascular structures leading into and within the
penis and that radiation damage to these may
mediate the decline in erectile function. The exact
physical structures involved with radiation-asso-
ciated ED have not been elucidated and continue to
be studied.
26 There is some evidence that lower
doses of radiation (o60–70Gy) given in the adju-
vant or salvage setting may be less damaging.
26,27
However, as primary radiation therapy contributes
to ED, it is possible that initiating radiation before
post-prostatectomy healing is complete may com-
pound men’s sexual difficulties.
Research on the sexual side effects of combined
surgical and radiation treatment is only beginning to
emerge and results are equivocal and incomplete
(Table 1). Hu et al.
28 reported a significantly worse
sexual functioning in men after post-operative
salvage radiation than after prostatectomy alone.
However, this was not a randomized study and risk
factors and treatments were not equally allocated
between those treated with surgery only and those
who received both surgery and radiation therapy.
Patients who underwent post-prostatectomy radia-
tion had a significantly higher likelihood of having
a pathologically high-risk disease (26 vs 12%,
Po0.01) and a trend toward a lower use of nerve-
sparing radical prostatectomy (57 vs 68%, Po0.06).
As a result, it is possible that the lower sexual
function scores were in part related to differences
in disease extent, surgical technique and use of
hormonal therapy. A prospective study by Formenti
et al.,
29 reported a survey of 255 patients 3 years
after radical prostatectomy, in which 94 (37%)
received 45–54Gy adjuvant postoperative radiation
therapy. They found no difference between the
adjuvant and observation groups in their ability
to maintain erectile functioning. Although these
results are encouraging, current radiation treatment
is delivered to a higher total radiation dose. There-
fore, these results may not be applicable to current
clinical practice.
30
Moinpour et al.
31 reported on prospective assess-
ments of the QOL outcomes for the SWOG 8794
randomized adjuvant radiation therapy trial. In their
report on 217 patients, who completed a Health-
Related Quality-of-Life (HRQOL) questionnaire after
surgery and before radiation therapy, the researchers
found no difference in erectile functioning between
107 patients who underwent radical prostatectomy
alone and those who had additional radiation
therapy. Both groups had highly prevalent
decreased erectile functioning in excess of 90%,
which probably does not reflect the current surgical
technique. There was no statistical difference
between the two groups with regard to ED, although
the combined therapy group’s erectile functioning
was consistently lower. This finding, in combina-
tion with the very high rate of ED in both groups,
limits the strength of the conclusion that radiation
does not detrimentally influence erectile function in
men who have preserved erectile function after
surgery.
The authors point out that the men report a
satisfactory overall QOL at 5 years after treatment, in
spite of low sexual functioning and significant
urinary frequency symptoms for the combined
treatment group. This conclusion contradicts other
QOL studies (Wei et al.
32—4-year follow-up, Sanda
et al.
23—2-year follow-up), which report that men
evidence significant bother regarding loss of erectile
functioning, thus indicating a less than acceptable
QOL. In Sanda’s study, partners also report being
bothered with regard to men’s sexual changes. Wei’s
and Sanda’s results are supported by Hedestig,
33
Bokhour,
34 Katz
35 and colleagues, who show that
men feel demoralized and emasculated by loss of
sexual functioning after prostate cancer treatment.
If, as suggested by Moinpour et al., after 5 years, men
report an overall high-health QOL, we may assume
that they have found a way to cope with the loss of
erection. However, we do not know whether
patients were content with the loss or whether their
partnered relationships accommodated this change
without losing intimacy. Further measuring
the sufficiency of erections for intercourse does
not represent the complex nature of partnered
sexuality. As little education is routinely offered to
prostate cancer patients and partners on how to
develop a new sexuality after treatment, couples
may anticipate life without satisfactory sexual
experiences,
36 and resort to compensatory rather
than effective coping.
37
Post-prostatectomy radiation and sexual health
D Wittmann et al
277
International Journal of Impotence ResearchT
a
b
l
e
1
S
e
x
u
a
l
f
u
n
c
t
i
o
n
i
n
g
a
f
t
e
r
c
o
m
b
i
n
e
d
R
P
a
n
d
R
T
S
t
u
d
y
P
r
o
s
p
e
c
t
i
v
e
v
s
r
e
t
r
o
s
p
e
c
t
i
v
e
V
a
l
i
d
a
t
e
d
i
n
s
t
r
u
m
e
n
t
P
r
e
-
o
p
a
s
s
e
s
s
m
e
n
t
P
r
e
-
R
T
a
s
s
e
s
s
m
e
n
t
P
o
s
t
-
R
T
a
s
s
e
s
s
m
e
n
t
P
a
t
i
e
n
t
o
r
p
h
y
s
i
c
i
a
n
r
e
p
o
r
t
e
d
o
u
t
c
o
m
e
F
i
n
d
i
n
g
s
S
o
u
t
h
W
e
s
t
O
n
c
o
l
o
g
y
G
r
o
u
p
(
S
W
O
G
,
M
o
i
n
p
o
u
r
e
t
a
l
.
3
1
)
P
r
o
s
p
e
c
t
i
v
e
r
a
n
d
o
m
i
z
e
d
a
d
j
u
v
a
n
t
v
s
o
b
s
e
r
v
a
t
i
o
n
N
¼
1
0
7
R
P
N
¼
1
1
0
R
P
þ
R
T
P
a
r
t
l
y
R
a
n
d
M
e
d
i
c
a
l
O
u
t
c
o
m
e
S
t
u
d
y
S
h
o
r
t
F
o
r
m
-
2
0
S
c
a
l
e
;
R
a
n
d
M
e
d
i
c
a
l
O
u
t
c
o
m
e
S
t
u
d
y
S
h
o
r
t
F
o
r
m
-
3
6
S
c
a
l
e
w
i
t
h
a
d
d
e
d
g
e
n
i
t
o
u
r
i
n
a
r
y
i
t
e
m
s
N
o
Y
e
s
Y
e
s
P
h
y
s
i
c
i
a
n
N
o
s
i
g
n
i
f
i
c
a
n
t
d
i
f
f
e
r
e
n
c
e
i
n
s
e
x
u
a
l
d
y
s
f
u
n
c
t
i
o
n
b
e
t
w
e
e
n
R
P
o
n
l
y
a
n
d
R
P
a
n
d
R
T
g
r
o
u
p
s
(
1
2
-
y
e
a
r
f
o
l
l
o
w
-
u
p
)
E
u
r
o
p
e
a
n
O
r
g
a
n
i
z
a
t
i
o
n
f
o
r
t
h
e
R
e
s
e
a
r
c
h
a
n
d
T
r
e
a
t
m
e
n
t
o
f
C
a
n
c
e
r
(
E
O
R
T
C
,
S
c
a
l
l
i
e
t
e
t
a
l
.
4
0
)
P
r
o
s
p
e
c
t
i
v
e
r
a
n
d
o
m
i
z
e
d
a
d
j
u
v
a
n
t
v
s
o
b
s
e
r
v
a
t
i
o
n
N
¼
5
0
2
R
P
N
¼
5
0
3
R
P
þ
R
T
P
a
r
t
l
y
Q
u
a
l
i
t
y
o
f
L
i
f
e
Q
u
e
s
t
i
o
n
n
a
i
r
e
—
C
-
3
0
a
n
d
a
n
a
d
h
o
c
p
r
o
s
t
a
t
e
t
r
e
a
t
m
e
n
t
-
s
p
e
c
i
f
i
c
q
u
e
s
t
i
o
n
n
a
i
r
e
d
e
v
e
l
o
p
e
d
f
o
r
t
h
e
s
t
u
d
y
N
o
N
o
Y
e
s
P
a
t
i
e
n
t
N
o
s
i
g
n
i
f
i
c
a
n
t
d
i
f
f
e
r
e
n
c
e
i
n
s
e
x
u
a
l
d
y
s
f
u
n
c
t
i
o
n
b
e
t
w
e
e
n
R
P
o
n
l
y
a
n
d
R
P
a
n
d
R
T
g
r
o
u
p
s
(
5
y
e
a
r
s
)
H
u
e
t
a
l
.
2
8
P
r
o
s
p
e
c
t
i
v
e
n
o
n
-
r
a
n
d
o
m
i
z
e
d
s
a
l
v
a
g
e
R
T
v
s
o
b
s
e
r
v
a
t
i
o
n
N
¼
1
2
2
0
R
P
N
¼
6
9
R
P
þ
R
T
Y
e
s
R
a
n
d
M
e
d
i
c
a
l
O
u
t
c
o
m
e
s
S
t
u
d
y
S
h
o
r
t
F
o
r
m
-
3
6
;
U
C
L
A
-
P
r
o
s
t
a
t
e
C
a
n
c
e
r
I
n
d
e
x
Y
e
s
N
o
Y
e
s
P
a
t
i
e
n
t
S
e
x
u
a
l
d
y
s
f
u
n
c
t
i
o
n
w
a
s
s
i
g
n
i
f
i
c
a
n
t
l
y
g
r
e
a
t
e
r
i
n
m
e
n
w
i
t
h
s
a
l
v
a
g
e
R
T
(
u
p
t
o
2
y
e
a
r
s
a
f
t
e
r
R
T
,
u
p
t
o
3
y
e
a
r
s
a
f
t
e
r
R
P
)
F
o
r
m
e
n
t
i
e
t
a
l
.
2
9
R
e
t
r
o
s
p
e
c
t
i
v
e
a
d
j
u
v
a
n
t
R
T
v
s
o
b
s
e
r
v
a
t
i
o
n
N
¼
1
8
9
R
P
N
¼
1
0
5
R
P
þ
R
T
N
o
C
l
i
n
i
c
a
l
i
n
t
e
r
v
i
e
w
s
p
r
e
-
o
p
e
r
a
t
i
v
e
l
y
,
1
a
n
d
3
y
e
a
r
s
p
o
s
t
o
p
e
r
a
t
i
v
e
l
y
Y
e
s
N
o
Y
e
s
P
a
t
i
e
n
t
N
o
s
i
g
n
i
f
i
c
a
n
t
d
i
f
f
e
r
e
n
c
e
i
n
s
e
x
u
a
l
d
y
s
f
u
n
c
t
i
o
n
b
e
t
w
e
e
n
R
P
o
n
l
y
a
n
d
R
P
a
n
d
R
T
g
r
o
u
p
s
(
3
þ
y
e
a
r
s
)
R
a
d
i
o
t
h
e
r
a
p
y
a
n
d
A
n
d
r
o
g
e
n
D
e
p
r
i
v
a
t
i
o
n
I
n
C
o
m
b
i
n
a
t
i
o
n
A
f
t
e
r
L
o
c
a
l
S
u
r
g
e
r
y
(
P
a
r
k
e
r
4
1
)
P
r
o
s
p
e
c
t
i
v
e
A
d
j
u
v
a
n
t
v
s
s
a
l
v
a
g
e
R
T
A
c
c
r
u
i
n
g
p
a
t
i
e
n
t
s
Y
e
s
E
u
r
o
Q
u
a
l
i
t
y
o
f
L
i
f
e
Q
u
e
s
t
i
o
n
n
a
i
r
e
I
n
t
e
r
n
a
t
i
o
n
a
l
C
o
n
t
i
n
e
n
c
e
S
o
c
i
e
t
y
–
M
a
l
e
s
-
S
F
R
a
n
d
M
e
d
i
c
a
l
O
u
t
c
o
m
e
S
t
u
d
y
S
h
o
r
t
F
o
r
m
-
1
2
S
c
a
l
e
;
V
a
i
z
e
y
I
n
c
o
n
t
i
n
e
n
c
e
Q
u
e
s
t
i
o
n
n
a
i
r
e
I
n
t
e
r
n
a
t
i
o
n
a
l
I
n
d
e
x
o
f
E
r
e
c
t
i
l
e
F
u
n
c
t
i
o
n
i
n
g
-
5
N
o
Y
e
s
Y
e
s
P
a
t
i
e
n
t
R
e
s
u
l
t
s
p
e
n
d
i
n
g
Post-prostatectomy radiation and sexual health
D Wittmann et al
278
International Journal of Impotence ResearchIt is possible to explain the combined therapy
group’s more frequent report of an improved QOL
over time by the difference in the use of salvage
hormonal therapy between the two groups, which
was not factored into the SWOG QOL study analysis;
the rate of salvage hormonal therapy at 5 years was
twice as high in the observation group as that in the
combined therapy patients (21 vs 10%, hazard ratio
0.45 (95% confidence interval: 0.29–0.68), Po0.001).
This difference in hormonal therapy was maintained
and increased over time. The lower use of salvage
hormonal therapy in the combined modality group
may have led to an overall better QOL—an associa-
tion also shown in another study.
23 Delay in the use
of androgen ablation through adjuvant may result in
a net improvement in sexual functioning. The
impact of adjuvant or salvage hormonal therapy on
erectile function merits further study.
The SWOG QOL analysis shows an increased
urinary frequency in a proportion of men treated on
the combined therapy arm as compared with the
observation arm (P¼0.002), with a consistent
increase of 15% in the proportion of patients
reporting frequent urination. Urinary symptoms
can be troubling to partners and can interfere with
sexual interest, pleasure and partnered sexual
activity.
38 To evaluate the effects of combined
therapy on sexual functioning, it would be neces-
sary to conduct an in-depth assessment that would
integrate body functions that affect sexuality and
emotional responses to those by the man, partner
and the couple. In addition, it is possible that efforts
to enhance urinary rehabilitation may have a
positive impact on sexual QOL in patients treated
with surgery with or without radiation therapy.
Overall, methodological problems undermine the
validity of the SWOG study’s findings. The study does
not include pre-prostatectomy erectile functioning
assessment, which makes it difficult to know what
sort of loss patients experienced from either surgery
alone or from the combined treatment. We know that
some men undergo prostate cancer treatment with
already existing ED,
23,39 which would presumably
have an effect on their and their partners’ adaptation.
As the SWOG trial did not include this baseline
assessment, long-term assessment will have limita-
tions. Finally, as these were physician-reported out-
comes and not all instruments were validated or
sensitive to patients’ feelings about their sexual
dysfunction, these findings are of limited value.
The EORTC study provides limited data on sexual
functioning after either surgery or combined treat-
ment. A mixture of validated (QOL C-30) and
nonvalidated (prostate treatment specific) question-
naires was used. However, assessment was carried
out only once any time between 2 months and
7 years after treatment (average 2 years) without a
follow-up of the evolution of side effects.
40
The RADICALS study uses validated measures of
QOL, including sexual functioning.
41 Assessments
begin postoperatively at randomization for radiation
therapy, and are repeated 1, 5 and 10 years later.
Unfortunately, preoperative sexual functioning will not
be assessed, once again missing an opportunity to
understand the change in sexual functioning that
patients will face. In addition, surveys of QOL factors,
although important in evaluating treatment toxicity, do
not include patients’ and couples’ adaptation and
hence need to be studied with a finer grain approach.
The evidence on the sexual side effects of
combined therapy is uneven and sometimes contra-
dictory. This is because of a number of factors: (1)
measurement was not sufficiently developed when
these studies began, thus making it impossible to
make comparisons across studies; (2) combination
therapy entailed varying dosages of radiation ther-
apy and different timing of post-prostatectomy
radiation; and (3) some patients may have received
additional hormonal therapy in the process of the
trial. The primary focus of these studies was on
relapse and survival prevention, thus making the
measurement of side effects more incidental. Since
the 1990s, valid and reliable measures have been
developed and can be used in prospective studies.
Penile rehabilitation
Penile rehabilitation has been developed in res-
ponse to men’s dissatisfaction with post-prostatec-
tomy erectile difficulties. It also offers hope of
recovering sexual intimacy to patients treated with
combined therapy. Research on outcomes associated
with nerve-sparing surgery suggests that nerve
sparing leads to a more successful erectile
recovery,
42–45 including the preservation of penile
length.
46 Patients are usually advised that they will
not know the extent of their recovery for up to
2 years.
4 To maintain penile tissue health during the
healing period, penile rehabilitation strategies
have been developed and continue to be studied
(Table 2). Some include daily low doses of phos-
phodiesterase type 5 (PDE-5) inhibitors or prosta-
glandin E to provide ongoing oxygenation of caver-
nosal tissues, and the use of vacuum evacuation
devices to promote penile stretching so that pre-
surgery penile size may be preserved.
47–51 Khera
52
suggests in a literature review that post-prostatect-
omy testosterone replacement therapy (TRT) may be
useful to patients who have problems with erections.
He and colleagues
53 report a retrospective review of
their erectile preservation program. A total of 99
patients underwent a course of preoperative and
postoperative nightly 25mg of sildenafil and
250mcg Medical Urethral System for Erection
(MUSE) suppositories three times a week, with
additional testosterone replacement therapy 1 month
after surgery added for hypogonadal men with
undetectable PSA and negative surgical margins.
Female partners were included in the study and
their sexual functioning was assessed pre- and
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ual functioning scores correlated significantly with
those of men and were predictive of men’s use of
intracavernosal injections. Combination therapy was
more effective than therapy with sildenafil alone.
Moreover, testosterone replacement helped 68% of
men achieve erection 9 months after surgery com-
pared with 12% of men in the non-testosterone
replacement therapy group. The value of early
pelvic-floor biofeedback was also found to be
effective in the rehabilitation process.
54 Although
this randomized trial was based on very small
numbers of participants, the treatment group was
able to show a better return to the ability to have
intercourse than was the control group.
Initial evidence suggests that early penile rehabilita-
tion leads to an increased chance of successful
recovery of spontaneous erections. As the concept of
penile rehabilitation has been developed and re-
searched to help with the side effects of prostatectomy,
its application to erectile recovery after radiation or
combined treatment (either alone or after surgical
therapy) and its effectiveness should be studied.
Furthermore, research on aids to erectile functioning
is extensive and offers hope to men whose ability to
attain a spontaneous erection is compromised.
Research on the use of penile injections, transurethral
suppositories and vacuum erectile devices is
ongoing,
45,55–58 but men and partners need counseling
and encouragement to take advantage of them.
Penile prostheses can be an ED treatment of choice
for those men who do not benefit from oral, injectable
or insertable medications, or for whom the desire for
spontaneity remains an overriding factor after prostate
cancer treatment. Urologists typically wait for 2 years
before offering this option on the basis of the time it
takes for nerve recovery when relevant, but patients
can choose to pursue it earlier. Although men tend to
be satisfied with the prosthesis,
55,59 one study cautions
that patients who are older and patients who undergo
radical prostatectomy do not find it as satisfactory as
does the general population.
60 Careful counseling
regarding expectations would be important as this is
a treatment that is not reversible.
Table 2 Aids to sexual recovery after post-prostatectomy radiation therapy (currently researched)
Pharmacological Physical Psycho-sexual
Penile rehabilitation options
(pretreatment)
Penile rehabilitation (pretreatment) Education (pretreatment)
Low-dose prostaglandin E
intracavernosal injections (5–10mcg) or
transurethral suppositories (125–250mcg)
periodically for 1 month or
Kegel exercises (3 sets of 10) daily Psychoeducation about the effect of
prostate cancer treatment on sexual
functioning
Low-dose phosphodiesterase 5 inhibitors
(1/2 tab every other day) for 1 month
Physical therapy for pelvic floor
rehabilitation
Psychoeducation about the typical
emotional responses that men and
partners experience in the aftermath of
prostate cancer treatment (grief and
mourning of old sexuality)
Penile rehabilitation options
(posttreatment)
Penile rehabilitation (posttreatment) Interventions (posttreatment)
Low-dose prostaglandin E
intracavernosal injections (5–10mcg) or
transurethral suppositories (125–250mcg)
every other day for 6 months or
Kegel exercises (3 sets of 10) daily Comprehensive psychosexual assessment
for the individual and couple
Low-dose phosphodiesterase 5 inhibitors
(1/2 dose every other day) for 6 months
Physical therapy for pelvic floor
rehabilitation
Psychoeducation about sexual recovery for
the man and for the couple: sexual
changes, feelings about them, need for
experimentation as a part of developing
new sexual relationship
Testosterone replacement Vacuum erectile devices (thrice a week) for
6 months
Sex therapy when couple has concerns
about resuming sexual relationship
Self-stimulation/masturbation (daily) for
6 months
Individual psychotherapy when man or
partner is having difficulty adapting to
new sexuality
Options of aids to erections Options of aids to erections Couple therapy when sexual issues are
embedded in long-term couple difficulties
Prostaglandin E intracavernosal injections
(5–20mcg) or transurethral suppositories
(125–1000mcg)
Vacuum erectile devices Support groups
Phosphodiesterase 5 inhibitors Vasoconstrictive rings Self-help books on sexuality after cancer
treatment
Post-prostatectomy radiation and sexual health
D Wittmann et al
280
International Journal of Impotence ResearchHelping patients make treatment decisions
Given the evidence that adjuvant radiation therapy
contributes positively to both biochemical control
and survival of prostate cancer after radical prosta-
tectomy with high-risk pathological features, a better
understanding of the impact of adjuvant or salvage
RT on sexuality is necessary. Radiation, adjuvant or
salvage, may negatively affect erection, but if it
prevents androgen ablation or disease recurrence, it
may represent a best, if difficult treatment, choice.
The balance between a desire for disease control
(even if it does not prolong life) and potential
negative effects on sexuality becomes complicated
and requires sensitivity to patient priorities. In
treatment choice discussions, providers can see
their role not as advocates of a particular treatment
but as guarantors of an opportunity for patients and
partners to consider survival, the sexual side effects
of treatment, and the signposts on a road map to
sexual recovery. Not all providers may feel comfor-
table assuming a role in which survival and QOL
concerns are discussed in the same breath.
61
Research into patients’ and partners’ attitudes
toward these choices would guide providers who
wish to promote a fruitful decision-making process
for patients and their partners.
A common assumption that survival overrides
concern about QOL has not always been borne out in
clinical practice because of concern that a life
without quality is not worth living.
62 This is of
particular concern with clinically localized prostate
cancer, wherein only a small proportion of patients
are ever likely to die of disease, whereas all treated
patients are subjected to risks of significant loss of
sexual functioning. What factors are at play when
the concern is not to end suffering, but to promote
intimacy, pleasure and vitality in a couple’s relation-
ship? Research into this area will be helpful in the
future, but there are some principles that can guide
advising patients and partners even now.
Many physicians are aware that patient and
partner-related factors are critical to sexual
recovery.
63 General research on patient decision
making in prostate cancer care suggests that patients
and their partners want to be informed and involved
in making decisions with regard to their cancer
treatment
64–67 and treatment for sexual dysfunction.
68
Provision of information may need to be individua-
lized and different cultural groups may place differ-
ent emphasis on sexual functioning. Awareness of
such differences would be critical while providing
counseling.
69–72 This may not reliably occur at this
time, particularly for gay men,
73 African Americans
70
and other ethnic groups.
74
As the side effects of prostate cancer surgery are
quite dramatic, uninformed patients would be more
susceptible to regretting their treatment choice.
Davison et al.
64 studied treatment regret in prostate
cancer and found that only a very small percentage
of men (4%, N¼140) regretted having decided on
surgical treatment despite significant sexual side
effects. However, Diefenbach et al.
75 reported regret
related to sexual bother and limitations because of
urinary incontinence in the first year after treatment.
It is not clear whether patients in those studies were
fully informed before making decisions, but it is
only human to regret a decision that leads to a
disability. The studies reported here represent
patient regret within the first year after treatment
when uncertainty about the resolution of treatment
side effects is at its peak.
Patients and partners for whom sexual intimacy is
vital and for whom its loss would be devastating
need to have an opportunity to evaluate (1) the risk
for recurrence and related lifespan if they do not opt
for adjuvant radiation, (2) thier likely response to
the recurrence of disease, and (3) treatments and
outcomes available in the salvage setting. Help
anticipating treatment regret due to frustrations
with side effects and their treatment could enable
men and partners develop realistic expectations for
physical functioning, as well as mitigate their
emotional responses during the course of the first
2 years after treatment when side effects are
resolving. According to Abelson et al.,
76 people
who suffer from anxiety are less likely to develop
symptoms when they are told to expect them.
Regardless of treatment choice, men can be
counseled on a number of strategies for sexual
recovery (Table 2). They can engage in penile
rehabilitation so as to maintain optimal physical
capacity for sexual recovery. In addition, all patients
and partners would benefit from being counseled
with regard to methods for maintaining intimacy,
despite diminished erectile functioning. Initial
research on intervention in the psycho-sexual
aspects of recovery from prostate cancer treatment
suggests that being informed and supported assists
with coping.
77–80 In a study by Titta et al.,
81
counseling successfully supported adherence to ED
treatment after prostate cancer treatment. But sexual
intimacy is not purely dependent on erection.
82 The
value and activities of nonpenetrative sexuality can
be discussed with a certified sex therapist (approved
by the American Association of Sexuality Educators,
Counselors and Therapists). Exercises such as
‘sensate focus’, which were originally developed
by Masters and Johnson,
83 are typically taught in sex
therapy to couples who wish to re-kindle or broaden
their sexual repertoire. They are ideal for the
vulnerable period of sexual recovery after prostate
cancer. New ideas on how partnered sexual pleasure
can be regained after sexual difficulties can be
taught in sex therapy and found in self-help books
that address sexual difficulties in a supportive and
realistic way.
84–86 With one notable exception,
87
current available self-help literature focuses on
heterosexual sexuality. We need self-help literature
and evidence-based interventions focused on the
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variety of ethnic groups so that their more specific
needs can be met. Couples would benefit from
being alerted to the emotional processing of sexual
changes through the work of grief and mourning so
that they can become emotionally ready to develop a
new, diverse sexuality beyond penetrative sex.
Healthcare providers are typically not easily able
to discuss sexual issues, but methods for such
conversations in prostate cancer care can be devel-
oped and promote comfort for both providers and
patients.
68 If patients feel that they can learn
strategies for retaining sexual intimacy, they can
maintain hope and actively pursue sexual recovery
regardless of treatment choice.
Summary
Clinical trials that begin preoperatively, compare
the timing of postoperative radiation, include
prospective assessments of sexual functioning
and couple functioning, and patients’ and partners’
concerns and wishes in this area are needed to help
providers who counsel patients during prostate
cancer treatment. In parallel, clinical trials of inter-
ventions that minimize the impact of postoperative
radiation on sexuality, aid in treatment decision
making and help couples maintain sexual intimacy
are vital to this effort. Multidisciplinary prostate
cancer care teams can maximize patients’ overall
life span and contribute to posttreatment QOL in the
patient’s intimate relationship.
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